Capital Market Strategies’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Capital Market Strategies’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$232K	Sell	3,627 -100	-3%	-$6.19K	0.16%	120
2025 Q1	$236K	Hold	3,727	–	–	0.16%	120
2024 Q4	$248K	Hold	3,727	–	–	0.14%	130
2024 Q3	$260K	Sell	3,727 -50	-1%	-$3.46K	0.16%	124
2024 Q2	$245K	Hold	3,777	–	–	0.15%	129
2024 Q1	$244K	Hold	3,777	–	–	0.19%	119
2023 Q4	$249K	Buy	3,777 +100	+3%	+$5.81K	0.22%	121
2023 Q3	$205K	Hold	3,677	–	–	0.2%	130
2023 Q2	$225K	Buy	+3,677	New	+$229K	0.21%	122
2023 Q1	–	Sell	-3,677	Closed	-$233K	–	104
2022 Q4	$233K	Hold	3,677	–	–	0.25%	109
2022 Q3	$217K	Hold	3,677	–	–	0.24%	113
2022 Q2	$212K	Hold	3,677	–	–	0.22%	127
2022 Q1	$228K	Sell	3,677 -1,050	-22%	-$64.1K	0.2%	131
2021 Q4	$337K	Buy	+4,727	New	+$342K	0.28%	91

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Capital Market Strategies's PBE Position: Q2 2025 in Review

Capital Market Strategies reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 2.7% in Q2 2025, selling an estimated $6.19K and leaving 3,627 shares worth $232K. The position accounts for 0.16% of the portfolio, ranked #120.

Capital Market Strategies first reported a position in PBE in Q4 2021 and has held it in 14 quarters since. The position peaked at $337K in Q4 2021. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2025.

Capital Market Strategies held 3,627 shares of Invesco Biotechnology & Genome ETF worth $232K as of Q2 2025.
Capital Market Strategies sold 100 Invesco Biotechnology & Genome ETF shares in Q2 2025, an estimated $6.19K.
Invesco Biotechnology & Genome ETF made up 0.16% of Capital Market Strategies's portfolio in Q2 2025, its #120 holding.
Capital Market Strategies first reported a position in Invesco Biotechnology & Genome ETF in Q4 2021 and has held it in 14 quarters since.
Capital Market Strategies's Invesco Biotechnology & Genome ETF position peaked at $337K in Q4 2021.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2025.

Based on Capital Market Strategies's 13F filing for Q2 2025, filed 2 Jul 2025.